Guided Therapeutics Inc. (OTCMKTS:GTHP) Sees Significant Decline in Short Interest

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 19,653 shares, a decline of 39.5% from the June 15th total of 32,466 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 17,349 shares, the days-to-cover ratio is currently 1.1 days.

Guided Therapeutics Price Performance

Guided Therapeutics stock remained flat at $0.27 during midday trading on Thursday. 23,501 shares of the company traded hands, compared to its average volume of 8,782. The stock has a 50-day moving average of $0.23 and a two-hundred day moving average of $0.29. The stock has a market capitalization of $26.07 million, a P/E ratio of -6.75 and a beta of 0.72. Guided Therapeutics has a one year low of $0.12 and a one year high of $0.54.

Guided Therapeutics (OTCMKTS:GTHP) last released its earnings results on Friday, May 15th. The company reported ($0.01) EPS for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.